Core Insights - The report highlights a strong growth trend in China's high-tech industries, with sales revenue increasing by 16.1% year-on-year in the first two months of the year, particularly driven by high-tech services and manufacturing sectors [2] - The report emphasizes the importance of economic globalization and China's role in providing certainty in a volatile global environment, as stated by the Ministry of Commerce [2] - The smart glasses market in China is projected to see significant growth, with an expected shipment volume of 2.46 million units in 2025, reflecting an 87.1% year-on-year increase [2] - The report outlines a strategic plan for the AI server industry in Shenzhen, aiming for substantial growth in production capacity and market share by 2028 [2] - The machine tool industry in China is showing signs of recovery, with a reported revenue of 288.7 billion yuan in 2025, marking a 10.3% year-on-year increase [5] Industry Summaries High-Tech Industry - High-tech service revenue grew by 17.2%, with significant increases in technology intermediary services and natural scientific research [2] - High-tech manufacturing revenue increased by 14.5%, driven by sectors such as aerospace and consumer electronics [2] Smart Glasses Market - The smart glasses market is expected to reach 2.46 million units shipped by 2025, with a growth rate of 87.1% [2] - The report notes that while the market is expanding rapidly, there are still challenges in realizing user value and effective market penetration [2] AI Server Industry - The Shenzhen action plan aims for a leap in AI server production and shipment by 2028, focusing on key components like core chips and storage [2] Machine Tool Industry - The machine tool sector is recovering, with a total revenue of 288.7 billion yuan and a 10.3% increase in 2025 [5] - The report indicates a positive trend in exports, which grew by 17.9% to reach 9.68 billion USD [5] Express Delivery Industry - In February 2026, the express delivery sector saw a business volume of approximately 12.11 billion packages, a year-on-year decline of 10.9%, but a 7.1% increase when considering January and February together [7][8] - The report notes that the industry is shifting focus from quantity to quality, with significant price increases observed in the express delivery sector [9]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Bao Pharmaceuticals Co., Ltd. 上海寶濟藥業股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2659） 自願公告 KJ103用於腎移植脫敏治療III期臨床試驗隨訪完成 本公告由上海寶濟藥業股份有限公司（「本公司」）作出，旨在向本公司股東及潛在 投資者提供有關本公司最新發展的資料。 本公司董事（「董事會」）欣然宣佈，KJ103作為脫敏療法用於中國等待腎臟移植的 高敏感患者的III期臨床試驗，已於2026年3月20日完成所有入組受試者的主要試 驗隨訪。本公司將盡快向國家藥品監督管理局（「國家藥監局」）提交新藥上市申 請。 承董事會命 上海寶濟藥業股份有限公司 董事長兼執行董事 關於KJ103 KJ103是一款全球首創、低免疫原性創新重組免疫球蛋白G (「IgG」)降解酶，用 於治療由病理性IgG抗體驅動的多種免疫介導疾病及病症。於2025年8月 ...

Group 1 - The core viewpoint of the article highlights that Baoyi Pharmaceutical-B (02659) has seen a significant stock price increase of over 6%, reaching a new high of 190 HKD, following its inclusion in the Hang Seng Composite Index as announced by the Hang Seng Index Company on February 13 [1] - The inclusion in the index is set to take effect after the market closes on March 6, 2026, and will expand the investment scope for the Hong Kong Stock Connect, potentially providing new growth opportunities for Baoyi Pharmaceutical [1] - Baoyi Pharmaceutical is recognized for its innovative products, including KJ017, the first recombinant hyaluronidase in China for large-volume subcutaneous administration, and KJ103, a globally first IgG degrading enzyme with best-in-class potential for antibody-mediated autoimmune diseases [1] Group 2 - The company has established a clear commercialization model and timeline for its upcoming and current products, with KJ017 expected to receive NDA approval in the first quarter of 2026 [1] - The long-acting follicle-stimulating hormone drug SJ02 has also been validated through collaboration, indicating the company's commitment to advancing its product pipeline in assisted reproduction [1]

Group 1 - The core viewpoint of the article highlights that Baoji Pharmaceutical-B (02659) has seen a significant stock price increase of over 6%, reaching a new high of 190 HKD, following its inclusion in the Hang Seng Composite Index [1] - The inclusion in the index will take effect after the market closes on March 6, 2026, and will expand the investment scope for the Hong Kong Stock Connect [1] - LiveReport's big data forecast suggests that Baoji Pharmaceutical is expected to leverage this opportunity to enter the Hong Kong Stock Connect, presenting new growth prospects [1] Group 2 - Baoji Pharmaceutical is known for its innovative products, including the first recombinant hyaluronidase KJ017 for large-volume subcutaneous administration, and the globally first IgG degrading enzyme KJ103, which has "best-in-class" potential for treating antibody-mediated autoimmune diseases [1] - The company has established a clear commercialization model and timeline for its upcoming and current products, with KJ017 expected to receive NDA approval in the first quarter of 2026 [1] - Currently, KJ017 is not marketed as a standalone therapy in China, indicating potential for future growth once approved [1]

Core Viewpoint - Baoyi Pharmaceutical-B (02659) has seen its stock price rise over 440% from its IPO price of 26.38 HKD, reaching a high of 143 HKD, indicating strong market interest and potential for future growth [1][5]. Group 1: Company Overview - Baoyi Pharmaceutical has developed three core products: KJ017, a recombinant hyaluronidase for large-volume subcutaneous administration; KJ103, an IgG degrading enzyme with "best-in-class" potential for autoimmune diseases; and SJ02, a long-acting follicle-stimulating hormone for assisted reproduction [1][5]. - These products are in various stages of commercialization, new drug application registration, or late-stage clinical trials in China, signaling a transition from pure research to commercialization for Baoyi Pharmaceutical [1][5]. Group 2: Financial Outlook - According to a report from Xiniu Securities, Baoyi Pharmaceutical has established a clear commercialization model and timeline, with expectations that its products will start contributing significantly to revenue by 2026, primarily from KJ017 and SJ02 [1][5]. - KJ103, which is aimed at desensitization in kidney transplantation, is projected to begin generating revenue in 2027, while its applications for GBS and anti-GBM diseases will contribute at a later date [1][5].

Core Viewpoint - Baoyi Pharmaceutical (02659) has seen its stock price increase by over 440% from its IPO price of 26.38 HKD, reaching a high of 143 HKD, indicating strong market interest and potential growth in its product pipeline [1] Group 1: Company Overview - Baoyi Pharmaceutical has developed China's first recombinant hyaluronidase KJ017 for large-volume subcutaneous administration, and the world's first IgG degrading enzyme KJ103, which shows "best-in-class" potential for low pre-storage antibodies and dosing frequency, targeting autoimmune diseases [1] - The company also has a long-acting follicle-stimulating hormone drug SJ02, which has been validated through collaboration and is aimed at assisted reproduction [1] Group 2: Commercialization and Revenue Potential - Baoyi Pharmaceutical is transitioning from a pure research phase to commercialization, with its three core products already in various stages of commercialization, new drug application registration, or late-stage clinical trials [1] - According to a report from Xiniu Securities, Baoyi has established a clear commercialization model and timeline, with expectations that products will start contributing significantly to revenue by 2026, particularly KJ017 and SJ02 [1] - The KJ103 product, used for kidney transplant desensitization, is anticipated to start generating revenue from 2027, while other applications for KJ103 will contribute at later stages [1]

Core Viewpoint - Shanghai Baoji Pharmaceutical Co., Ltd. successfully listed on the Hong Kong Stock Exchange, achieving a market capitalization exceeding HKD 20 billion on its first day, demonstrating resilience and strategic foresight in a challenging market environment [1] Group 1: Company Growth and Strategy - Baoji Pharmaceutical has demonstrated a pattern of "counter-cyclical" growth, choosing to expand its R&D pipeline during economic downturns, such as the COVID-19 pandemic in 2019 and the tightening financing environment in 2022 [1] - The company emphasizes a clear strategic principle of either being the first or the only in its chosen fields, focusing on unmet clinical needs rather than competing in crowded markets [2] Group 2: Innovative Products - The company’s product SJ02 is the first long-acting follicle-stimulating hormone approved in China, addressing the needs of women facing fertility challenges with a more convenient treatment regimen [3] - KJ103, a novel IgG-degrading enzyme, targets acute autoimmune diseases, providing a new treatment pathway for conditions that have been traditionally difficult to manage [3] Group 3: Cost Management and Manufacturing - Baoji Pharmaceutical prioritizes cost management and efficiency in its manufacturing processes, aiming to make effective treatments accessible to a broader population [4][5] - The company has established a GMP-compliant production facility and is developing a second facility to enhance its manufacturing capabilities, which is expected to be operational by mid-2026 [5] Group 4: Market Expansion and Future Plans - The company plans to use approximately HKD 922 million raised from its IPO for the further development and commercialization of its core products, with a significant portion allocated to global market expansion [7] - Baoji Pharmaceutical aims to submit clinical trial applications for its products in Europe by mid-2026, indicating a commitment to international growth and collaboration with multinational pharmaceutical companies [7][8] Group 5: Industry Context - The Chinese innovative drug market is experiencing significant growth, with a notable increase in licensing agreements, although many biotech firms face challenges in R&D and commercialization capabilities [8][9] - Baoji Pharmaceutical's strategy contrasts with the trend of "selling seedlings," as it focuses on self-research and independent market entry, aiming to build a globally recognized pharmaceutical brand [9]

Core Viewpoint - The Hong Kong IPO market for biotech companies has experienced extreme differentiation, with Baoyi Pharmaceutical achieving a significant surge in stock price while Huasheng Biotechnology and Hansai Aitai faced substantial declines, reflecting a shift in investor sentiment and valuation criteria in the sector [1][2][3]. Market Overview - The Hong Kong biotech IPO market in 2025 showed a "hot then cold" trend, with the first half benefiting from global market recovery and supportive policies, leading to significant first-day gains for new listings [2][3]. - December marked a turning point, with Baoyi Pharmaceutical's listing on December 10 serving as a watershed moment, followed by a sharp decline in the stock prices of Huasheng Biotechnology and Hansai Aitai shortly thereafter [3][4]. Market Shift Factors - The extreme differentiation in stock performance is attributed to multiple pressures in the Hong Kong IPO market, including stricter regulatory requirements and a significant increase in the number of new listings, leading to a higher rate of stock price declines [5][6]. - The biotech sector is facing valuation pressure as previous high valuations are reassessed against fundamental performance, with investors focusing on pipeline certainty and commercial viability [6]. Pipeline Comparison - Baoyi Pharmaceutical's "pyramid" pipeline strategy balances certainty and growth, focusing on clinically validated products and innovative therapies, while Huasheng Biotechnology and Hansai Aitai struggle with slow clinical progress and high uncertainty [7][10][12]. - Baoyi's pipeline includes products like SJ02 and KJ017, which have clear market potential and established clinical pathways, contrasting with Huasheng's limited and delayed pipeline [7][12]. Financial Health - Baoyi Pharmaceutical has demonstrated initial self-sustaining revenue capabilities, with significant revenue growth driven by commercialized products, while Hansai Aitai and Huasheng Biotechnology lack main business income and face escalating losses [15][18][20]. - Baoyi's financial position is bolstered by a strong cash reserve and successful fundraising, while Hansai Aitai and Huasheng Biotechnology are at risk of operational disruption due to cash flow constraints [17][19][21]. Commercialization Potential - Baoyi Pharmaceutical's products target large and growing markets, supported by strong partnerships, enhancing its commercial viability [22][23]. - In contrast, Hansai Aitai and Huasheng Biotechnology face significant challenges in commercializing their products due to intense competition and limited market acceptance [24][25]. Valuation Logic Shift - The valuation logic in the biotech sector has shifted from speculative "story-driven" assessments to a more rational "value-driven" approach, emphasizing pipeline certainty and financial sustainability [26][27][28]. - Baoyi Pharmaceutical's success is attributed to its clear commercial pathways and financial health, while Huasheng and Hansai Aitai's struggles highlight the risks of lacking fundamental support [28][30]. Investor Sentiment - The differentiation in stock performance reflects a broader trend of investors moving towards value-based assessments, focusing on core competencies and sustainable business models [31][32]. - The market is expected to continue favoring companies with strong fundamentals, while those lacking such support may face increasing scrutiny and potential exclusion from investor interest [32].

Core Viewpoint - Baoyi Pharmaceutical successfully listed on the Hong Kong Stock Exchange on December 10, 2025, with an issue price of HKD 26.38 per share and a base issuance scale of approximately HKD 1 billion [1]. Group 1: Company Overview - Baoyi Pharmaceutical was established in 2019, focusing on four strategic areas: (i) large-volume subcutaneous delivery, (ii) antibody-mediated autoimmune diseases, (iii) assisted reproduction, and (iv) recombinant biopharmaceuticals [2]. - The company has a pipeline of 12 self-developed products, including three core products: SJ02 (a long-acting recombinant human follicle-stimulating hormone), KJ017 (a recombinant hyaluronidase), and KJ103 (an innovative recombinant immunoglobulin G degrading enzyme) [2]. - The total clinical addressable market size for the company's four strategic therapeutic areas in China is projected to reach approximately RMB 50 billion by 2033 [2]. Group 2: Investment and Market Position - The company has established commercial-scale production capabilities, enabling cost-effective and standardized production, which provides a cost advantage and allows for business expansion into other therapeutic areas [2]. - Three cornerstone investors participated in the IPO, accounting for approximately 20.06% of the shares offered [2]. - Shenyin Wanguo Securities (Hong Kong) acted as the joint bookrunner and lead underwriter for the IPO, leveraging its market experience and investor coverage to support the company's listing [3].

Core Viewpoint - The Hong Kong stock market's 18A biotech sector is experiencing a resurgence in IPOs, with a significant shift in investor sentiment towards a more cautious evaluation of companies based on commercial maturity, cash flow sustainability, and clear value propositions, reshaping valuation methodologies across the industry [1] Group 1: Strategic Positioning - Baijia Pharmaceutical's strategic positioning focuses on avoiding "red ocean" competition in ADC and PD-1 fields, instead targeting traditional process upgrades and clinical application scenario transformations, which allows for shorter and more certain commercialization [2] - The founder's diverse background enables the company to accurately identify real clinical needs and hidden major products, avoiding common pitfalls in drug development [2] - Core products like KJ017 and SJ02 aim to enhance patient quality of life and medication convenience, effectively circumventing price pressures from national medical insurance [2] Group 2: Technological Barriers - The advanced biomanufacturing platform, represented by synthetic biology, is a core tool for Baijia Pharmaceutical's strategic differentiation [3] - The company has built a high-barrier biomanufacturing platform over six years, addressing challenges in large-scale expression, activity retention, and ultra-efficient purification of difficult recombinant enzymes [3] - The platform's zero animal-source production eliminates risks of viral contamination and severe allergic reactions, creating a "safety barrier" that cannot be undermined by price competition [3] Group 3: Industrialized Operations - Baijia Pharmaceutical integrates its technological advantages with industrialized operational capabilities to establish a "total cost leadership" structural moat [4] - Unlike many biotech companies relying on external CDMOs, Baijia Pharmaceutical has built and expanded large-scale cGMP production bases, becoming one of the few companies with commercial-scale production lines for mammalian, yeast, and E. coli fermentation [4] Group 4: Pipeline Structure - The synergy of strategic choice, technological barriers, and industrial advantages has led to Baijia Pharmaceutical's unique "pyramid-shaped" pipeline layout [6] - The base of the pipeline consists of products with short clinical cycles, low costs, and high market demand certainty, such as SJ02 and KJ017, which provide stable sales and cash flow [6] - The innovative projects at the top of the pyramid, like KJ103, are positioned as groundbreaking therapies with significant potential in treating autoimmune diseases, establishing the company as a high-value innovation engine [6] Group 5: Growth Model - Baijia Pharmaceutical's diversified and layered "two-legged" growth model enables it to achieve continuous, stable, and gradually increasing "slope-type" growth, avoiding the traditional "step-up" gambling model reliant on single product success [7] - This approach demonstrates the company's comprehensive competitiveness and long-term sustainability under the new valuation system [7] Summary - Baijia Pharmaceutical's rise is attributed to the organic synergy between its unique strategic positioning, technological pathways, production capabilities, and pipeline structure [8] - In a context where the biopharmaceutical industry faces "involution" challenges, the company offers a new innovation paradigm by focusing on clinical scenario innovation, technological upgrades, and strategic resilience [8]